首页> 美国卫生研究院文献>The Canadian Journal of Cardiology >Implantable cardioverter defibrillator: Charge saver not syncope saver!
【2h】

Implantable cardioverter defibrillator: Charge saver not syncope saver!

机译:植入式心脏复律除颤器:节省费用而不是晕厥保护程序!

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In patients with an implantable cardioverter defibrillator, empirical anti-tachycardia pacing/burst pacing (ATP) is associated with a significantly decreased rate of appropriate shocks. The use of ATP as first-line therapy in ventricular tachycardia promotes less pain and better quality of life because the number of shocks is reduced. Additionally, battery longevity is substantially increased with this strategy. Based on this, device manufacturers have developed new algorithms to optimize the use of ATP and shocks in patients with an implantable cardioverter defibrillator. The present report describes a case in which the use of one of these new algorithms was associated with a significant delay in tachycardia termination and, consequently, led to syncope.
机译:对于具有植入式心脏复律除颤器的患者,经验性抗心动过速起搏/爆发起搏(ATP)与适当电击率显着降低有关。 ATP作为心动过速的一线治疗方法,可减少电击次数,从而减轻疼痛并改善生活质量。此外,使用此策略可大大提高电池寿命。基于此,设备制造商开发了新的算法,以优化植入式心脏复律除颤器患者的ATP使用和电击。本报告描述了一种情况,其中使用这些新算法之一与心动过速终止的显着延迟有关,因此导致晕厥。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号